Login / Signup

Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.

Phil McEwanOliver DarlingtonRyan MillerJohn J V McMurrayDavid C WheelerHiddo J Lambers HeerspinkAndrew BriggsKlas BergenheimJuan Jose Garcia Sanchez
Published in: Clinical journal of the American Society of Nephrology : CJASN (2022)
Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD), NCT03036150.
Keyphrases
  • chronic kidney disease
  • end stage renal disease
  • healthcare
  • public health
  • mental health
  • climate change
  • social media
  • replacement therapy
  • human health
  • smoking cessation
  • peritoneal dialysis